S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.42 (+1.84%)
AAPL   111.70 (+1.47%)
MSFT   207.55 (+2.47%)
FB   254.39 (+2.51%)
GOOGL   1,459.85 (+2.08%)
AMZN   3,129.00 (+5.69%)
NVDA   504.25 (+0.71%)
TSLA   421.54 (-6.20%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.23 (-1.89%)
MU   49.69 (+1.10%)
AMD   77.67 (-0.35%)
T   28.52 (-0.38%)
F   6.78 (-1.31%)
ACB   7.44 (+17.72%)
GILD   63.48 (-1.14%)
NFLX   490.92 (+0.73%)
DIS   127.30 (+1.51%)
BAC   23.96 (-2.08%)
BA   156.85 (+0.32%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.42 (+1.84%)
AAPL   111.70 (+1.47%)
MSFT   207.55 (+2.47%)
FB   254.39 (+2.51%)
GOOGL   1,459.85 (+2.08%)
AMZN   3,129.00 (+5.69%)
NVDA   504.25 (+0.71%)
TSLA   421.54 (-6.20%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.23 (-1.89%)
MU   49.69 (+1.10%)
AMD   77.67 (-0.35%)
T   28.52 (-0.38%)
F   6.78 (-1.31%)
ACB   7.44 (+17.72%)
GILD   63.48 (-1.14%)
NFLX   490.92 (+0.73%)
DIS   127.30 (+1.51%)
BAC   23.96 (-2.08%)
BA   156.85 (+0.32%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.42 (+1.84%)
AAPL   111.70 (+1.47%)
MSFT   207.55 (+2.47%)
FB   254.39 (+2.51%)
GOOGL   1,459.85 (+2.08%)
AMZN   3,129.00 (+5.69%)
NVDA   504.25 (+0.71%)
TSLA   421.54 (-6.20%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.23 (-1.89%)
MU   49.69 (+1.10%)
AMD   77.67 (-0.35%)
T   28.52 (-0.38%)
F   6.78 (-1.31%)
ACB   7.44 (+17.72%)
GILD   63.48 (-1.14%)
NFLX   490.92 (+0.73%)
DIS   127.30 (+1.51%)
BAC   23.96 (-2.08%)
BA   156.85 (+0.32%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.42 (+1.84%)
AAPL   111.70 (+1.47%)
MSFT   207.55 (+2.47%)
FB   254.39 (+2.51%)
GOOGL   1,459.85 (+2.08%)
AMZN   3,129.00 (+5.69%)
NVDA   504.25 (+0.71%)
TSLA   421.54 (-6.20%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.23 (-1.89%)
MU   49.69 (+1.10%)
AMD   77.67 (-0.35%)
T   28.52 (-0.38%)
F   6.78 (-1.31%)
ACB   7.44 (+17.72%)
GILD   63.48 (-1.14%)
NFLX   490.92 (+0.73%)
DIS   127.30 (+1.51%)
BAC   23.96 (-2.08%)
BA   156.85 (+0.32%)
Log in
NASDAQ:RARE

Ultragenyx Pharmaceutical Stock Forecast, Price & News

$82.81
+2.36 (+2.93 %)
(As of 09/22/2020 03:59 PM ET)
Add
Compare
Today's Range
$77.55
Now: $82.81
$82.83
50-Day Range
$72.98
MA: $82.30
$87.96
52-Week Range
$31.99
Now: $82.81
$91.77
Volume12,242 shs
Average Volume516,436 shs
Market Capitalization$5.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.23
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
Read More
Ultragenyx Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.27 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARE
CUSIPN/A
Phone415-483-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$103.71 million
Book Value$11.32 per share

Profitability

Net Income$-402,730,000.00
Net Margins-188.51%

Miscellaneous

EmployeesN/A
Market Cap$5.02 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$82.81
+2.36 (+2.93 %)
(As of 09/22/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

How has Ultragenyx Pharmaceutical's stock price been impacted by Coronavirus?

Ultragenyx Pharmaceutical's stock was trading at $45.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RARE shares have increased by 79.9% and is now trading at $81.60.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Ultragenyx Pharmaceutical?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ultragenyx Pharmaceutical
.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Ultragenyx Pharmaceutical
.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) issued its earnings results on Thursday, July, 30th. The biopharmaceutical company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($1.56) by $0.74. The biopharmaceutical company had revenue of $61.71 million for the quarter, compared to the consensus estimate of $40.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 56.12% and a negative net margin of 188.51%.
View Ultragenyx Pharmaceutical's earnings history
.

What price target have analysts set for RARE?

15 brokerages have issued 12 month price targets for Ultragenyx Pharmaceutical's shares. Their forecasts range from $64.00 to $99.00. On average, they anticipate Ultragenyx Pharmaceutical's stock price to reach $82.38 in the next year. This suggests a possible upside of 1.0% from the stock's current price.
View analysts' price targets for Ultragenyx Pharmaceutical
.

Are investors shorting Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical saw a drop in short interest in August. As of August 14th, there was short interest totaling 6,840,000 shares, a drop of 14.7% from the July 30th total of 8,020,000 shares. Based on an average trading volume of 450,900 shares, the short-interest ratio is presently 15.2 days. Approximately 12.2% of the shares of the company are sold short.
View Ultragenyx Pharmaceutical's Short Interest
.

Who are some of Ultragenyx Pharmaceutical's key competitors?

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Pfizer (PFE), Exelixis (EXEL), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Micron Technology (MU), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP) and GALAPAGOS NV/S (GLPG).

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the following people:
  • Emil D. Kakkis, President, Chief Executive Officer & Director
  • Wladimir Hogenhuis, Chief Operating Officer
  • Shalini Sharp, Chief Financial Officer & Executive Vice President
  • Dennis Karl Huang, Chief Technical Operations Officer & Senior VP
  • Eric Crombez, Chief Medical Officer

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.48%), Federated Hermes Inc. (6.73%), Macquarie Group Ltd. (2.52%), FMR LLC (2.38%), First Trust Advisors LP (1.96%) and Bank of New York Mellon Corp (1.25%). Company insiders that own Ultragenyx Pharmaceutical stock include Clay B Siegall, Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski.
View institutional ownership trends for Ultragenyx Pharmaceutical
.

Which institutional investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Barclays PLC, First Light Asset Management LLC, UBS Group AG, Hudson Bay Capital Management LP, Macquarie Group Ltd., Prudential Financial Inc., and CHI Advisors LLC. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Clay B Siegall, Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, and Theodore Alan Huizenga.
View insider buying and selling activity for Ultragenyx Pharmaceutical
.

Which institutional investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Vanguard Group Inc., Nuveen Asset Management LLC, New York State Common Retirement Fund, Federated Hermes Inc., Bank of New York Mellon Corp, TD Asset Management Inc., and Two Sigma Advisers LP.
View insider buying and selling activity for Ultragenyx Pharmaceutical
.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $81.60.

How big of a company is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has a market capitalization of $4.94 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis.

What is Ultragenyx Pharmaceutical's official website?

The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.